Literature DB >> 25962453

[Hyperuricemia - more than gout : Impact on cardiovascular risk and renal insufficiency].

L Sellin1, J T Kielstein, K de Groot.   

Abstract

BACKGROUND: Hyperuricemia is not only associated with gout but also with hypertension, atherosclerosis and chronic kidney disease (CKD); however, in cases of disproportionally high serum uric acid levels without symptoms of gout and slowly progressive chronic kidney failure especially in young people, a genetic cause of hyperuricemia needs to be considered. PATHOGENETIC ASSOCIATIONS: The results of experimental studies suggest that hyperuricemia can be a pathophysiologically relevant cardiovascular risk factor. In animal studies hyperuricemia leads to oxidative stress and vascular dysfunction and chronically elevated uric acid levels can result in structural changes of the vessel wall. Epidemiological data show a connection between hyperuricemia and hypertension and uric acid lowering therapy has been shown to lower arterial blood pressure. In CKD, uric acid increases in parallel with the decline in GFR and an increase in proteinuria. Several ongoing prospective clinical trials will clarify if pharmacological lowering of uric acid will translate into reduction of relevant cardiovascular and renal endpoints. THERAPY: The treatment of gout and the medicinal prophylaxis of further gout attacks depend on the comorbidities and especially CKD.

Entities:  

Mesh:

Year:  2015        PMID: 25962453     DOI: 10.1007/s00393-014-1481-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  44 in total

1.  Hyperuricemia in severe pulmonary hypertension.

Authors:  M A Voelkel; K M Wynne; D B Badesch; B M Groves; N F Voelkel
Journal:  Chest       Date:  2000-01       Impact factor: 9.410

Review 2.  Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease.

Authors:  Atsushi Enomoto; Hitoshi Endou
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

3.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

4.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

Review 5.  Uric acid and chronic kidney disease: which is chasing which?

Authors:  Richard J Johnson; Takahiko Nakagawa; Diana Jalal; Laura Gabriela Sánchez-Lozada; Duk-Hee Kang; Eberhard Ritz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

Review 6.  Mechanisms of uric acid crystal-mediated autoinflammation.

Authors:  Fabio Martinon
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

7.  Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial.

Authors:  Awsan Noman; Donald S C Ang; Simon Ogston; Chim C Lang; Allan D Struthers
Journal:  Lancet       Date:  2010-06-09       Impact factor: 79.321

8.  Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Christian Mallen; Weiya Zhang; Michael Doherty
Journal:  JAMA       Date:  2014 Dec 24-31       Impact factor: 56.272

9.  Gout and the risk for incident heart failure and systolic dysfunction.

Authors:  Eswar Krishnan
Journal:  BMJ Open       Date:  2012-02-15       Impact factor: 2.692

10.  Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.

Authors:  Hyun Ah Kim; Young-Il Seo; Yeong W Song
Journal:  J Korean Med Sci       Date:  2014-07-30       Impact factor: 2.153

View more
  3 in total

1.  Zisheng Shenqi decoction ameliorates monosodium urate crystal-induced gouty arthritis in rats through anti-inflammatory and anti-oxidative effects.

Authors:  Jieru Han; Ying Xie; Fangyu Sui; Chunhong Liu; Xiaowei Du; Chenggang Liu; Xiaoling Feng; Deyou Jiang
Journal:  Mol Med Rep       Date:  2016-07-18       Impact factor: 2.952

2.  Clinical characteristics of patients under 40 years old with early-onset hyperuricaemia: a retrospective monocentric study in China.

Authors:  Yi Zhang; Yong Yang; Leixi Xue; Jian Wen; Lin Bo; Mei Tang; Ru Yang; Dong Yan; Zhichun Liu
Journal:  BMJ Open       Date:  2019-08-27       Impact factor: 2.692

Review 3.  The molecular mechanisms of hemodialysis vascular access failure.

Authors:  Akshaar Brahmbhatt; Andrea Remuzzi; Marco Franzoni; Sanjay Misra
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.